MedWatch

Novo Nordisk hopes to stabilize Wegovy supply in early 2022

Production of obesity drug Wegovy is still expected to experience delays for the rest of 2021, but should, however, be stabilized in early 2022, the pharmaceutical company reports.

Photo: Novo Nordisk / PR

Novo Nordisk has significantly increased the production of its weight loss drug Wegovy, which is in high demand, and is now hoping to have stabilized its supply early next year, the company writes in an update on its website.

Depending on the demand for the drug, production may still be affected by delays for the rest of 2021, before stabilizing in 2022.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs